Role of nucleoside transporters in nucleoside-derived drug sensitivity

Nucleosides, Nucleotides and Nucleic Acids

Volumn 29, Issue 4-6, 2010, Pages 335-346

  Molina Arcas, M ^a,b   Pastor Anglada, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

chemotherapy; nucleoside analogs; Nucleoside transporters; SLC28; SLC29; tumor

Indexed keywords

5' NUCLEOTIDASE; CAPECITABINE; CLADRIBINE; CLOFARABINE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; CYTARABINE; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; FLUDARABINE; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 8; NITROBENZYLTHIOINOSINE; NUCLEOSIDE DIPHOSPHATE KINASE; NUCLEOSIDE MONOPHOSPHATE KINASE; NUCLEOSIDE TRANSPORTER; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE 1; TROXACITABINE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG ACTIVATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION AND TRANSLATION; HAPLOTYPE; HUMAN; MANTLE CELL LYMPHOMA; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES;

EID: 77953689270     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257771003729823     Document Type: Review

References (54)

1. Baldwin, S.A.; Beal, P.R.; Yao, S.Y.; King, A.E.; Cass, C.E.; Young, J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004, 447(5), 735-743.
2. Gray, J.H.; Owen, R.P.; Giacomini, K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 2004, 447(5), 728-734.
3. Sabini, E.; Ort, S.; Monnerjahn, C.; Konrad, M.; Lavie, A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat. Struct. Biol. 2003, 10(7), 513-559
4. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15(6), 875-890.
5. Spychala, J.; Madrid-Marina, V.; Fox, I.H. Evidence for "low Km" and "high Km" soluble 5 - nucleotidases in human tissues and rat liver. Adv. Exp. Med. Biol. 1989, 253B, 129-134.
6. Brockman, R.W.; Schabel, F.M., Jr.; Montgomery, J.A. Biologic activity of 9-beta-D-arabinofuranosyl- 2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. Biochem. Pharmacol. 1977, 26(22), 2193-2196.
7. Reid, G.; Wielinga, P.; Zelcer, N.; De Haas, M.; Van Deemter, L.; Wijnholds, J.; Balzarini, J.; Borst, P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 2003, 63(5), 1094-1103.
8. Pratt, S.; Shepard, R.L.; Kandasamy, R.A.; Johnston, P.A.; Perry,W., 3rd; Dantzig, A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther. 2005, 4(5), 855-863.
9. Guo, Y.; Kotova, E.; Chen, Z.S.; Lee, K.; Hopper-Borge, E.; Belinsky, M.G.; Kruh, G.D. MRP8, ATPbinding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′- dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J. Biol. Chem. 2003, 278(32), 29509-29514.
10. Jordheim, L.; Galmarini, C.M.; Dumontet, C. Drug resistance to cytotoxic nucleoside analogues. Curr. Drug Targets. 2003, 4(6), 443-460.
11. Mini, E.; Nobili, S.; Caciagli, B.; Landini, I.; Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol. 2006, 17(Suppl. 5), v7-v12.
12. Baldwin, S.A.; Yao, S.Y.; Hyde, R.J.; Ng, A.M.; Foppolo, S.; Barnes, K.; Ritzel, M.W.; Cass, C.E.; Young, J.D. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellularmembranes. J. Biol. Chem. 2005, 280(16), 15880-15887.
13. Barnes, K.; Dobrzynski, H.; Foppolo, S.; Beal, P.R.; Ismat, F.; Scullion, E.R.; Sun, L.; Tellez, J.; Ritzel, M.W.; Claycomb, W.C.; Cass, C.E.; Young, J.D.; Billeter-Clark, R.; Boyett, M.R.; Baldwin, S.A. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ. Res. 2006, 99(5), 510-519.
14. Molho-Pessach, V.; Lerer, I.; Abeliovich, D.; Agha, Z.; Abu Libdeh, A.; Broshtilova, V.; Elpeleg, O.; Zlotogorski, A. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am. J. Hum. Genet. 2008, 83(4), 529-534.
15. Govindarajan, R.; Leung, G.P.; Zhou, M.; Tse, C.M.; Wang, J.; Unadkat, J.D. Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009, 296(4), G910-G922.
16. Smith, K.M.; Ng, A.M.; Yao, S.Y.; Labedz, K.A.; Knaus, E.E.; Wiebe, L.I.; Cass, C.E.; Baldwin, S.A.; Chen, X.Z.; Karpinski, E.; Young, J.D. Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J. Physiol. 2004, 558(Pt 3), 807-823.
17. Hu, H.; Endres, C.J.; Chang, C.; Umapathy, N.S.; Lee, E.W.; Fei, Y.J.; Itagaki, S.; Swaan, P.W.; Ganapathy, V.; Unadkat, J.D. Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol. Pharmacol. 2006, 69(5), 1542-1553.
18. Lang, T.T.; Selner, M.; Young, J.D.; Cass, C.E. Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol. Pharmacol. 2001, 60(5), 1143-1152.
19. Lu, H.; Chen, C.; Klaassen, C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab. Dispos. 2004, 32(12), 1455-1461.
20. Valdes, R.; Ortega, M.A.; Casado, F.J.; Felipe, A.; Gil, A.; Sanchez-Pozo, A.; Pastor-Anglada, M. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology 2000, 119(6), 1623-1630.
21. Ritzel, M.W.; Ng, A.M.; Yao, S.Y.; Graham, K.; Loewen, S.K.; Smith, K.M.; Ritzel, R.G.; Mowles, D.A.; Carpenter, P.; Chen, X.Z.; Karpinski, E.; Hyde, R.J.; Baldwin, S.A.; Cass, C.E.; Young, J.D. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem. 2001, 276(4), 2914-2927.
22. Dragan, Y.; Valdes, R.; Gomez-Angelats, M.; Felipe, A.; Javier Casado, F.; Pitot, H.; Pastor-Anglada, M. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology 2000, 32(2), 239-246.
23. Pennycooke, M.; Chaudary, N.; Shuralyova, I.; Zhang, Y.; Coe, I.R. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys. Res. Commun. 2001, 280(3), 951-959.
24. Farre, X.; Guillen-Gomez, E.; Sanchez, L.; Hardisson, D.; Plaza, Y.; Lloberas, J.; Casado, F.J.; Palacios, J.; Pastor-Anglada, M. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer 2004, 112(6), 959-966.
25. Mackey, J.R.; Jennings, L.L.; Clarke, M.L.; Santos, C.L.; Dabbagh, L.; Vsianska, M.; Koski, S.L.; Coupland, R.W.; Baldwin, S.A.; Young, J.D.; Cass, C.E. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res. 2002, 8(1), 110-116.
26. Soler, C.; Valdes, R.; Garcia-Manteiga, J.; Xaus, J.; Comalada, M.; Casado, F.J.; Modolell, M.; Nicholson, B.; MacLeod, C.; Felipe, A.; Celada, A.; Pastor-Anglada, M. Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms. J. Biol. Chem. 2001, 276(32), 30043-30049.
27. Soler, C.; Garcia-Manteiga, J.; Valdes, R.; Xaus, J.; Comalada, M.; Casado, F.J.; Pastor-Anglada, M.; Celada, A.; Felipe, A. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J. 2001, 15(11), 1979-1988.
28. Aymerich, I.; Pastor-Anglada, M.; Casado, F.J. Long term endocrine regulation of nucleoside transporters in rat intestinal epithelial cells. J. Gen. Physiol. 2004, 124(5), 505-512.
29. Gloeckner-Hofmann, K.; Guillen-Gomez, E.; Schmidtgen, C.; Porstmann, R.; Ziegler, R.; Stoss, O.; Casado, F.J.; Ruschoff, J.; Pastor-Anglada, M. Expression of the high-affinity fluoropyrimidinepreferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 2006, 70(3), 238-244.
30. Mackey, J.R.; Galmarini, C.M.; Graham, K.A.; Joy, A.A.; Delmer, A.; Dabbagh, L.; Glubrecht, D.; Jewell, L.D.; Lai, R.; Lang, T.; Hanson, J.; Young, J.D.; Merle-Beral, H.; Binet, J.L.; Cass, C.E.; Dumontet, C. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 2005, 105(2), 767-774.
31. Mackey, J.R.; Mani, R.S.; Selner, M.; Mowles, D.; Young, J.D.; Belt, J.A.; Crawford, C.R.; Cass, C.E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998, 58(19), 4349-5437.
32. Gourdeau, H.; Clarke, M.L.; Ouellet, F.; Mowles, D.; Selner, M.; Richard, A.; Lee, N.; Mackey, J.R.; Young, J.D.; Jolivet, J.; Lafreniere, R.G.; Cass, C.E. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res. 2001, 61(19), 7217-7224.
33. Zimmerman, E.I.; Huang, M.; Leisewitz, A.V.; Wang, Y.; Yang, J.; Graves, L.M. Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett. 2009, 583(2), 425-429.
34. Cai, J.; Damaraju, V.L.; Groulx, N.;Mowles, D.; Peng, Y.; Robins, M.J.; Cass, C.E.; Gros, P. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 2008, 68(7), 2349-2357.
35. Molina-Arcas, M.; Moreno-Bueno, G.; Cano-Soldado, P.; Hernandez-Vargas, H.; Casado, F.J.; Palacios, J.; Pastor-Anglada, M. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells. Biochem. Pharmacol. 2006, 72(12), 1646-1656.
36. Mata, J.F.; Garcia-Manteiga, J.M.; Lostao, M.P.; Fernandez-Veledo, S.; Guillen-Gomez, E.; Larrayoz, I.M.; Lloberas, J.; Casado, F.J.; Pastor-Anglada, M. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol. Pharmacol. 2001, 59(6), 1542-2158
37. Garcia-Manteiga, J.; Molina-Arcas, M.; Casado, F.J.; Mazo, A.; Pastor-Anglada, M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidineinduced cytotoxicity. Clin. Cancer Res. 2003, 9(13), 5000-5008.
38. Cano-Soldado, P.; Molina-Arcas, M.; Alguero, B.; Larrayoz, I.; Lostao, M.P.; Grandas, A.; Casado, F.J.; Pastor-Anglada, M. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. Biochem. Pharmacol. 2008, 75(3), 639-648.
39. Gati, W.P.; Paterson, A.R.; Larratt, L.M.; Turner, A.R.; Belch, A.R. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 1997, 90(1), 346-353.
40. Galmarini, C.M.; Thomas, X.; Calvo, F.; Rousselot, P.; Rabilloud, M.; El Jaffari, A.; Cros, E.; Dumontet, C. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 2002, 117(4), 860-868.
41. Hubeek, I.; Stam, R.W.; Peters, G.J.; Broekhuizen, R.; Meijerink, J.P.; van Wering, E.R.; Gibson, B.E.; Creutzig, U.; Zwaan, C.M.; Cloos, J.; Kuik, D.J.; Pieters, R.; Kaspers, G.J. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 2005, 93(12), 1388-11394.
42. Marce, S.; Molina-Arcas, M.; Villamor, N.; Casado, F.J.; Campo, E.; Pastor-Anglada, M.; Colomer, D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006, 91(7), 895-902.
43. Molina-Arcas, M.; Bellosillo, B.; Casado, F.J.; Montserrat, E.; Gil, J.; Colomer, D.; Pastor-Anglada, M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003, 101(6), 2328-2334. (Pubitemid 36304669)
44. Lopez-Guerra, M.; Trigueros-Motos, L.; Molina-Arcas, M.; Villamor, N.; Casado, F.J.; Montserrat, E.; Campo, E.; Colomer, D.; Pastor-Anglada, M. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica 2008, 93(12), 1843-1851.
45. Rozman, C.; Montserrat, E. Chronic lymphocytic leukemia. N. Engl. J. Med. 1995, 333(16), 1052-1057.
46. Stoetzer, O.J.; Pogrebniak, A.; Scholz, M.; Pelka-Fleischer, R.; Gullis, E.; Darsow, M.; Nussler, V.; Wilmanns, W. Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia 1999, 13(11), 1873-1880.
47. Spratlin, J.; Sangha, R.; Glubrecht, D.; Dabbagh, L.; Young, J.D.; Dumontet, C.; Cass, C.; Lai, R.; Mackey, J.R. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 2004, 10(20), 6956-6961.
48. Giovannetti, E.; Del Tacca, M.; Mey, V.; Funel, N.; Nannizzi, S.; Ricci, S.; Orlandini, C.; Boggi, U.; Campani, D.; Del Chiaro, M.; Iannopollo, M.; Bevilacqua, G.; Mosca, F.; Danesi, R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006, 66(7), 3928-3935.
49. Farrell, J.J.; Elsaleh, H.; Garcia, M.; Lai, R.; Ammar, A.; Regine, W.F.; Abrams, R.; Benson, A.B.; Macdonald, J.; Cass, C.E.; Dicker, A.P.; Mackey, J.R. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1), 187-195.
50. Tsang, R.Y.; Santos, C.; Ghosh, S.; Dabbagh, L.; King, K.; Young, J.; Cass, C.E.;Mackey, J.R.; Lai, R. Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Mod. Pathol. 2008, 21(11), 1387-1393.
51. Errasti-Murugarren, E.; Molina-Arcas, M.; Casado, F.J.; Pastor-Anglada, M. A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum. FASEB J. 2009, 23(1), 172-182.
52. Myers, S.N.; Goyal, R.K.; Roy, J.D.; Fairfull, L.D.; Wilson, J.W.; Ferrell, R.E. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics 2006, 16(5), 315-320.
53. Nakano, Y.; Tanno, S.; Koizumi, K.; Nishikawa, T.;Nakamura, K.;Minoguchi, M.; Izawa, T.;Mizukami, Y.; Okumura, T.; Kohgo, Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 2007, 96(3), 457-463.
54. Andersson, R.; Aho, U.; Nilsson, B.I.; Peters, G.J.; Pastor-Anglada, M.; Rasch, W.; Sandvold, M.L. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scand. J. Gastroenterol. 2009, 1-5.